Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2023-03-30 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document details share issuance under a share award plan, share counts before and after issuance, and includes confirmations by the company's executive director and CEO. The document is structured as a regulatory disclosure of share capital changes rather than a full financial report or announcement of a report. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result. It is a formal notification of share capital changes as required by listing rules. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is under 5,000 characters but contains substantive data on share issuance and confirmations, so it is not merely an announcement but the actual disclosure report.
2023-03-30 Chinese
百济神州有限公司关于2023年年度股东大会股权登记日的公告
AGM Information Classification · 95% confidence The document is an announcement from BeiGene Ltd. regarding the record date for the 2023 Annual General Meeting (AGM) of shareholders. It specifies the exact dates and times for the share registration across different stock exchanges and jurisdictions to determine shareholder eligibility for attending and voting at the AGM. The document also mentions that further details about the AGM such as meeting date, location, agenda, and voting procedures will be disclosed later. The document is short (1408 characters) and serves as a notice about the AGM record date rather than the AGM materials or minutes themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM event itself. The document is not a full annual report, financial report, or voting results announcement. Hence, the classification is AGM-R with high confidence.
2023-03-29 Chinese
港股公告：百济神州有限公司截至2022年12月31日止年度全年业绩公告
Annual Report Classification · 100% confidence The document is a comprehensive financial report for BeiGene, Ltd. covering the full fiscal year ended December 31, 2022, with comparative figures for 2021. It includes detailed financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity statements. The report is prepared according to US GAAP and reviewed by the audit committee. It contains extensive notes on accounting policies, organizational structure, and prior period restatements. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly identify it as an official annual report covering the company's full financial performance for the year. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-03-29 Chinese
港股公告：员工购股权计划
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the 2018 Employee Stock Purchase Plan (ESPP) of BeiGene, Ltd., detailing the subscription period, eligibility, purchase price, and other plan specifics. It references compliance with listing rules and provides detailed terms of the stock purchase plan for employees. The document does not contain financial statements, earnings data, or management discussion of financial results. It is not a report but an announcement about a capital-related employee stock plan. This fits best under the category of Share Issue/Capital Change (SHA), as it relates to issuance of shares under an employee stock purchase plan.
2023-03-17 Chinese
港股公告：审计委员会会议日期
Report Publication Announcement Classification · 95% confidence The document is a short announcement (879 characters) from BeiGene, Ltd. regarding the date of the Audit Committee meeting to review and approve the full year results for the fiscal year ended December 31, 2022. It references that the full year results were previously announced on February 27, 2023, and filed with the SEC as a Form 10-K. The announcement clarifies that the results to be published under the Hong Kong Listing Rules are the same as those previously filed with the SEC, except for additional disclosures required by the Hong Kong rules. The document does not contain the full annual report or detailed financial statements itself but is an announcement about the timing and content of the upcoming audit committee meeting and the forthcoming publication of the annual results. Given the short length and the nature of the content, this fits the definition of a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself or an Audit Report (AR).
2023-03-17 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It details share issuance under an employee share scheme, share counts before and after issuance, and includes confirmations from the company's executive director and CEO. The document is structured as a regulatory disclosure of share capital changes rather than a full financial report or announcement of a report. It fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital changes.
2023-03-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.